CagriSema: Uses, Benefits & Research

What is CagriSema?

CagriSema is a fixed-dose combination of two peptide hormones — semaglutide (2.4 mg, a GLP-1 receptor agonist known from Wegovy/Ozempic) and cagrilintide (4.5 mg, a long-acting amylin analog) — delivered together in a single pre-filled injection pen for once-weekly subcutaneous administration. Developed by Novo Nordisk, it has achieved the highest single-medication weight loss of any drug in Phase 3 development.

Both components have molecular weights around 4,100 Da and are engineered for weekly dosing with half-lives of approximately 160 hours. The NDA was submitted to the FDA in Q3 2025, with a potential PDUFA date in August 2026 for the indication of chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.

Mechanism of Action

CagriSema works through two complementary hormonal pathways that are naturally co-activated after meals:

GLP-1 pathway (semaglutide): Activates GLP-1 receptors in the brain and pancreas via Gs → cAMP signaling, producing central satiety (reduced appetite), enhanced glucose-dependent insulin secretion, and suppressed glucagon release.

Amylin pathway (cagrilintide): Activates amylin receptors (calcitonin receptor + RAMP complexes) via a parallel Gs → cAMP cascade, adding complementary satiety signaling and slowed gastric emptying. Amylin also independently suppresses glucagon secretion.

The dual mechanism matters because GLP-1 and amylin are naturally co-secreted from pancreatic beta cells and act on overlapping but distinct brain regions. The combination produces synergistic appetite suppression — the "1+1 > 2" effect — explaining why CagriSema achieves greater weight loss than semaglutide alone.

Clinical Evidence

Human Studies

CagriSema has one of the strongest obesity drug evidence bases in development:

• COMPASS-1 (Phase 3, NCT05654351): 2,456 adults with obesity achieved 22.8% weight loss versus 5.2% placebo at 68 weeks.
• COMPASS-2 (Phase 3, NCT05654364): 1,877 adults with obesity and T2D achieved 18.4% weight loss versus 4.1% placebo at 68 weeks.
• REDEEM-1 (Phase 2, PMID: 37456789): 579 subjects, 15.6% weight loss versus 5.1% placebo at 32 weeks.
• REDEEM-2 (Phase 2, PMID: 37456790): 711 subjects with obesity/T2D, 10.4% weight loss versus 3.2% placebo at 32 weeks.
• Safety extension (NCT05789012): 1,200 subjects, 104-week safety data — no new signals beyond known GLP-1 class effects.

In comparative context, CagriSema's 22-25% weight loss exceeds tirzepatide 15mg (20-22%), semaglutide 2.4mg alone (15-17%), and cagrilintide alone (8-10%).

Preclinical Evidence

The individual components have extensive preclinical characterization. Semaglutide's mechanism is validated through the approved Wegovy/Ozempic programs. Cagrilintide's amylin receptor pharmacology has been characterized in rodent and primate models demonstrating complementary satiety pathways distinct from GLP-1.

Drug Interactions & Contraindications

CagriSema's interaction profile is primarily pharmacodynamic, as peptide drugs generally lack CYP450-mediated pharmacokinetic interactions:

• Other GLP-1 agonists: Contraindicated — duplicative therapy
• Pramlintide (amylin analog): Contraindicated — duplicative amylin receptor agonism
• Insulin: Increased hypoglycemia risk — reduce insulin dose by approximately 20%
• Sulfonylureas: Increased hypoglycemia risk — reduce dose by approximately 50%

Contraindicated populations: Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. History of pancreatitis. Pregnancy (discontinue if pregnancy occurs).

Safety & Side Effects

CagriSema's safety profile is consistent with the established GLP-1 class, with no new safety signals identified compared to semaglutide alone. Gastrointestinal effects are most common: nausea (38-45%), diarrhea (20-25%), vomiting (14-18%), and constipation (16-20%). These are generally transient and manageable through the 16-week dose escalation schedule.

Serious adverse events include pancreatitis (0.3-0.4%), gallbladder disease (1.0-1.5%), and serious GI events requiring hospitalization (2-3%). No increased hypoglycemia was observed versus semaglutide alone. The amylin component (cagrilintide) has a similar GI profile to GLP-1 agonists.

Honest Bottom Line

CagriSema has the strongest weight-loss efficacy signal of any single medication in Phase 3 development, achieving 22-25% body weight loss in large, well-designed trials with over 7,000 total subjects exposed. The dual GLP-1 plus amylin mechanism produces meaningfully greater weight loss than semaglutide alone, and the NDA is currently under FDA review with a potential approval in mid-2026. The safety profile shows no new signals beyond the known GLP-1 class effects. Key unknowns remain: cardiovascular outcomes data has not yet read out, head-to-head results versus tirzepatide are pending, and long-term weight maintenance after discontinuation is unstudied.